AU661360B2 - Novel cytokine - Google Patents

Novel cytokine Download PDF

Info

Publication number
AU661360B2
AU661360B2 AU31226/93A AU3122693A AU661360B2 AU 661360 B2 AU661360 B2 AU 661360B2 AU 31226/93 A AU31226/93 A AU 31226/93A AU 3122693 A AU3122693 A AU 3122693A AU 661360 B2 AU661360 B2 AU 661360B2
Authority
AU
Australia
Prior art keywords
cells
sequence
ser
leu
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU31226/93A
Other languages
English (en)
Other versions
AU3122693A (en
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Srinivasan Subhashini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU661360(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU3122693A publication Critical patent/AU3122693A/en
Application granted granted Critical
Publication of AU661360B2 publication Critical patent/AU661360B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU31226/93A 1991-10-25 1992-10-23 Novel cytokine Expired AU661360B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US783707 1991-10-25
US80572391A 1991-12-05 1991-12-05
US805723 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (2)

Publication Number Publication Date
AU3122693A AU3122693A (en) 1993-05-21
AU661360B2 true AU661360B2 (en) 1995-07-20

Family

ID=27120174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31226/93A Expired AU661360B2 (en) 1991-10-25 1992-10-23 Novel cytokine

Country Status (12)

Country Link
EP (2) EP0667901B2 (enExample)
JP (2) JP3308534B2 (enExample)
KR (1) KR100283541B1 (enExample)
AT (2) ATE239790T1 (enExample)
AU (1) AU661360B2 (enExample)
CA (2) CA2312667C (enExample)
DE (2) DE69233051T2 (enExample)
DK (3) DK0822199T3 (enExample)
ES (2) ES2198025T3 (enExample)
FI (2) FI116850B (enExample)
NO (2) NO317625B1 (enExample)
WO (1) WO1993008207A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677788B2 (en) * 1992-09-04 1997-05-08 Bristol-Myers Squibb Company Soluble ligands for CD40

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
ATE256180T1 (de) * 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
AU676227B2 (en) * 1993-01-22 1997-03-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
NZ273208A (en) * 1993-09-02 2000-12-22 Dartmouth College Suppressing a humoral immune response against a thymus dependant (TD) antigen
ES2120067T3 (es) * 1993-09-02 1998-10-16 Dartmouth College Metodos para inducir tolerancia de celulas t antigeno especifica.
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
WO1995017202A1 (en) * 1993-12-23 1995-06-29 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
DK0812206T3 (da) * 1995-03-01 2002-09-09 Immunex Corp Fremgangsmåde til stimulering af en immunrespons
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
JP3279573B2 (ja) * 1995-06-07 2002-04-30 イミュネックス・コーポレーション 新規の変異型cd40l
DK0833847T3 (da) * 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0910474B1 (en) * 1996-06-14 2004-03-24 University of Washington Absorption-enhanced differential extraction method
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
JP2002514418A (ja) 1998-05-14 2002-05-21 イミュネックス・コーポレーション 破骨細胞活性の阻害方法
PL219605B1 (pl) * 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
JP2003533488A (ja) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 免疫抑制を達成するための組成物および方法
US7288252B2 (en) 2000-10-02 2007-10-30 Novartis Vaccines And Diagnostics, Inc. Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
ES2675735T3 (es) 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1434871B1 (en) 2001-09-20 2017-01-18 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2004074439A2 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-cd154 항체
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CA2584211C (en) 2004-10-22 2014-07-08 Amgen Inc. Methods for refolding of recombinant antibodies
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
US20100226925A1 (en) 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
BRPI0819229B1 (pt) 2007-11-01 2019-01-22 The Board Of Trustees Of The University Of Arkansas vacinas para reforçar reações imunes contra eimeria
ES2579231T3 (es) 2008-01-15 2016-08-08 Abbvie Inc Vectores de expresión de mamíferos mejorados y usos de los mismos
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
NZ601609A (en) 2010-01-21 2014-08-29 Univ Arkansas Vaccine vectors and methods of enhancing immune responses
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
WO2014127185A1 (en) 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
BR112018002319A2 (pt) 2015-08-05 2018-12-11 Janssen Biotech, Inc. anticorpos anti-cd154 e métodos de uso dos mesmos
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
AU2017260323B2 (en) 2016-05-03 2023-11-16 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
EA201892588A1 (ru) 2016-05-11 2019-06-28 Амген Инк. Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
AU2018223821B2 (en) 2017-02-27 2022-05-19 Shattuck Labs, Inc. TIGIT- and LIGHT-based chimeric proteins
CN110381974A (zh) * 2017-02-27 2019-10-25 沙塔克实验室有限公司 基于csf1r的嵌合蛋白

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627710B2 (en) * 1988-02-25 1992-09-03 General Hospital Corporation, The Rapid immunoselection cloning method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627710B2 (en) * 1988-02-25 1992-09-03 General Hospital Corporation, The Rapid immunoselection cloning method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677788B2 (en) * 1992-09-04 1997-05-08 Bristol-Myers Squibb Company Soluble ligands for CD40

Also Published As

Publication number Publication date
DE69233051D1 (de) 2003-06-12
FI941837L (fi) 1994-05-30
EP0667901A4 (en) 1995-06-22
NO941422D0 (no) 1994-04-19
EP0897983B1 (en) 2003-05-07
ES2227513T3 (es) 2005-04-01
DK0822199T3 (da) 2004-12-27
CA2121798C (en) 2007-07-24
HK1019343A1 (en) 2000-02-03
DE69233402T3 (de) 2009-06-25
ES2198025T3 (es) 2004-01-16
EP0897983A2 (en) 1999-02-24
EP0667901A1 (en) 1995-08-23
EP0667901B2 (en) 2008-10-15
NO941422L (enExample) 1994-06-27
AU3122693A (en) 1993-05-21
DK0897983T3 (da) 2003-08-11
JPH07504083A (ja) 1995-05-11
FI116850B (fi) 2006-03-15
JPH10150994A (ja) 1998-06-09
NO320073B1 (no) 2005-10-17
ES2227513T5 (es) 2009-04-01
DK0667901T4 (da) 2008-11-10
KR100283541B1 (ko) 2001-03-02
NO980030L (no) 1998-01-05
FI941837A0 (fi) 1994-04-20
ATE239790T1 (de) 2003-05-15
CA2312667C (en) 2002-11-19
CA2312667A1 (en) 1993-04-29
FI116828B (fi) 2006-03-15
JP3308534B2 (ja) 2002-07-29
EP0897983A3 (en) 1999-03-17
FI981765L (fi) 1998-08-17
CA2121798A1 (en) 1993-04-29
ATE274055T1 (de) 2004-09-15
FI981765A0 (fi) 1998-08-17
WO1993008207A1 (en) 1993-04-29
DE69233051T2 (de) 2004-03-11
NO980030D0 (no) 1998-01-05
DE69233402T2 (de) 2005-09-15
JP2877788B2 (ja) 1999-03-31
DK0667901T3 (da) 2004-12-27
DE69233402D1 (de) 2004-09-23
EP0667901B1 (en) 2004-08-18
NO317625B1 (no) 2004-11-29

Similar Documents

Publication Publication Date Title
AU661360B2 (en) Novel cytokine
US6290972B1 (en) Method of augmenting a vaccine response by administering CD40 ligand
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
AU693713B2 (en) CD40L mutein
EP0817847B1 (en) Il-17 receptor
US5783665A (en) Cytokine which is a ligand for OX40
US20030144182A1 (en) CD40-Ligand lacking native-pattern glycosylation
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE
HK1019343B (en) Antibody against cd40-l